Patients Using AUSTEDO XR® (deutetrabenazine) Extended-Release Tablets Experience Symptom Relief and High Levels of Satisfaction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 21 2025
0mins
Should l Buy TEVA?
Source: Newsfilter
Patient Satisfaction with AUSTEDO XR: A survey of 209 patients with tardive dyskinesia (TD) revealed that over 94% experienced movement improvement after treatment with AUSTEDO XR, with 89% expressing high satisfaction and 96% finding the medication easy to take.
Impact on Quality of Life: Patients reported enhanced social and emotional well-being due to reduced movements, with more than 77% agreeing that their improved condition led to greater comfort in social settings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.120
Low
29.00
Averages
35.71
High
40.00
Current: 30.120
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TEVA ACHIEVES BIOSIMILAR PROGRESS WITH U.S. FDA APPROVAL OF PONLIMSI™ (DENOSUMAB-ADET) AND ACCEPTANCE OF DUAL FILING FOR BIOSIMILAR CANDIDATE TO XOLAIR® (OMALIZUMAB)
Teva's Recent Developments: Teva has gained approval from the U.S. FDA for its biosimilar product, PONLIMSI™ (denosumab-abd).
Dual Filing Acceptance: The company has also received acceptance for a dual filing related to its biosimilar candidate, Toxolair® (omalizumab).
See More
Teva's Biosimilar PONLIMSI Receives FDA Approval
- FDA Approval of PONLIMSI: Teva's biosimilar PONLIMSI (denosumab-adet) has received FDA approval for all indications of Prolia® (denosumab), including treatment for postmenopausal women and men at high risk for fractures, marking a significant advancement in Teva's biosimilars portfolio and furthering its growth strategy.
- Xolair® Biosimilar Application Accepted: Teva's applications for its proposed biosimilar candidate to Xolair® (omalizumab) have been accepted by both the FDA and EMA, covering all indications such as allergic asthma and chronic rhinosinusitis, showcasing Teva's strong potential and competitiveness in the biosimilars market.
- Milestone in Strategic Transformation: The FDA approval and application acceptances not only highlight Teva's robust capabilities in biosimilar R&D but also reflect the success of its Pivot to Growth strategy, which is expected to yield long-term market opportunities and revenue growth for the company.
- Global Market Expansion: With the FDA approval of PONLIMSI, Teva is poised to strengthen its position in the global biosimilars market, addressing the increasing patient demand while laying the groundwork for future innovations and expansion of its product portfolio.
See More
Teva Receives FDA Approval for New Biosimilar Drug
- Biosimilar Approval: Teva Pharmaceutical's Ponlimsi (denosumab-adet) has received FDA approval as a biosimilar to Amgen's Prolia (denosumab), which is projected to generate approximately $4.4 billion in revenue in 2025, indicating Teva's potential in the osteoporosis treatment market.
- Increased Market Competition: As Prolia is Amgen's best-selling drug, Teva's approval may exert competitive pressure, potentially leading to a decline in Prolia's market share, which could adversely affect Amgen's revenue and market position.
- Regulatory Review Progress: Teva also announced that the FDA and the European Medicines Agency have agreed to review its biosimilar applications for Genentech and Novartis' Xolair (omalizumab), which reported sales of approximately $3.8 billion and $1.7 billion in 2025, respectively, showcasing Teva's expansion potential in respiratory disease treatments.
- Optimistic Industry Outlook: With the FDA relaxing testing rules for biosimilars, Teva's applications are likely to receive more support, potentially driving growth for other generic drug suppliers in the industry, thereby enhancing market competition and drug accessibility.
See More
Analysis of FNDF ETF's 52-Week Price Range
- Price Range Analysis: FNDF ETF's 52-week low is $31.915 per share and high is $52.935, with the latest trade at $47.68, indicating relative stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market dynamics.
See More
Teva Receives FDA Approval for New Biosimilar
- FDA Approval: Teva Pharmaceutical Industries announced that its biosimilar PONLIMSI has received FDA approval as a biosimilar to Prolia for treating various debilitating bone conditions, marking a significant advancement in its biosimilar portfolio.
- Clinical Data Support: The FDA's approval was based on a totality of evidence, including analytical and clinical data demonstrating similar efficacy, safety, and immunogenicity profiles compared to Prolia, enhancing Teva's competitive position in the market.
- New Candidate Applications: Teva's applications for a proposed biosimilar candidate to Xolair have been accepted by both the U.S. FDA and the European Medicines Agency, further expanding its biosimilar product offerings and demonstrating the company's proactive strategy in the global market.
- Market Reaction: In pre-market trading, TEVA shares were priced at $28.61, down 0.47%, reflecting a cautious market response to the new drug approval, but potentially increasing the company's market share in the biopharmaceutical sector in the long run.
See More
FNDF ETF 52-Week Price Analysis
- Price Range Analysis: FNDF ETF's 52-week low is $31.915 per share and high is $52.935, with the latest trade at $47.66, indicating relative stability and investment appeal in the current market.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend analysis and investment timing decisions.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market dynamics.
See More
TEVA ACHIEVES BIOSIMILAR PROGRESS WITH U.S. FDA APPROVAL OF PONLIMSI™ (DENOSUMAB-ADET) AND ACCEPTANCE OF DUAL FILING FOR BIOSIMILAR CANDIDATE TO XOLAIR® (OMALIZUMAB)
Teva's Recent Developments: Teva has gained approval from the U.S. FDA for its biosimilar product, PONLIMSI™ (denosumab-abd).
Dual Filing Acceptance: The company has also received acceptance for a dual filing related to its biosimilar candidate, Toxolair® (omalizumab).
See More
Teva's Biosimilar PONLIMSI Receives FDA Approval
- FDA Approval of PONLIMSI: Teva's biosimilar PONLIMSI (denosumab-adet) has received FDA approval for all indications of Prolia® (denosumab), including treatment for postmenopausal women and men at high risk for fractures, marking a significant advancement in Teva's biosimilars portfolio and furthering its growth strategy.
- Xolair® Biosimilar Application Accepted: Teva's applications for its proposed biosimilar candidate to Xolair® (omalizumab) have been accepted by both the FDA and EMA, covering all indications such as allergic asthma and chronic rhinosinusitis, showcasing Teva's strong potential and competitiveness in the biosimilars market.
- Milestone in Strategic Transformation: The FDA approval and application acceptances not only highlight Teva's robust capabilities in biosimilar R&D but also reflect the success of its Pivot to Growth strategy, which is expected to yield long-term market opportunities and revenue growth for the company.
- Global Market Expansion: With the FDA approval of PONLIMSI, Teva is poised to strengthen its position in the global biosimilars market, addressing the increasing patient demand while laying the groundwork for future innovations and expansion of its product portfolio.
See More
Teva Receives FDA Approval for New Biosimilar Drug
- Biosimilar Approval: Teva Pharmaceutical's Ponlimsi (denosumab-adet) has received FDA approval as a biosimilar to Amgen's Prolia (denosumab), which is projected to generate approximately $4.4 billion in revenue in 2025, indicating Teva's potential in the osteoporosis treatment market.
- Increased Market Competition: As Prolia is Amgen's best-selling drug, Teva's approval may exert competitive pressure, potentially leading to a decline in Prolia's market share, which could adversely affect Amgen's revenue and market position.
- Regulatory Review Progress: Teva also announced that the FDA and the European Medicines Agency have agreed to review its biosimilar applications for Genentech and Novartis' Xolair (omalizumab), which reported sales of approximately $3.8 billion and $1.7 billion in 2025, respectively, showcasing Teva's expansion potential in respiratory disease treatments.
- Optimistic Industry Outlook: With the FDA relaxing testing rules for biosimilars, Teva's applications are likely to receive more support, potentially driving growth for other generic drug suppliers in the industry, thereby enhancing market competition and drug accessibility.
See More
Analysis of FNDF ETF's 52-Week Price Range
- Price Range Analysis: FNDF ETF's 52-week low is $31.915 per share and high is $52.935, with the latest trade at $47.68, indicating relative stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market dynamics.
See More
Teva Receives FDA Approval for New Biosimilar
- FDA Approval: Teva Pharmaceutical Industries announced that its biosimilar PONLIMSI has received FDA approval as a biosimilar to Prolia for treating various debilitating bone conditions, marking a significant advancement in its biosimilar portfolio.
- Clinical Data Support: The FDA's approval was based on a totality of evidence, including analytical and clinical data demonstrating similar efficacy, safety, and immunogenicity profiles compared to Prolia, enhancing Teva's competitive position in the market.
- New Candidate Applications: Teva's applications for a proposed biosimilar candidate to Xolair have been accepted by both the U.S. FDA and the European Medicines Agency, further expanding its biosimilar product offerings and demonstrating the company's proactive strategy in the global market.
- Market Reaction: In pre-market trading, TEVA shares were priced at $28.61, down 0.47%, reflecting a cautious market response to the new drug approval, but potentially increasing the company's market share in the biopharmaceutical sector in the long run.
See More
FNDF ETF 52-Week Price Analysis
- Price Range Analysis: FNDF ETF's 52-week low is $31.915 per share and high is $52.935, with the latest trade at $47.66, indicating relative stability and investment appeal in the current market.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend analysis and investment timing decisions.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying assets and market dynamics.
See More
